Optimized Antiplatelet Therapy on the Prognosis of ACS Patients With Non-predominant Coronary Artery Disease After PCI

NCT04338919 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

2020

Enrollment

OTHER

Sponsor class

Conditions

Acute Coronary Syndrome
Percutaneous Coronary Intervention

Interventions

PROCEDURE: Percutaneous coronary intervention
DRUG: Ticagrelor plus aspirin

Sponsor

Fujian Medical University